For over a hundred years, the deal has been simple. You have Type 1 diabetes, your immune system kills your insulin. So, you inject insulin. It keeps you alive.
But it does not stop the war inside your body.
Insulin shots are a patch, not a fix. The immune system keeps attacking the beta cells. Slowly. Relentlessly. Until they are all gone. Scientists have been trying to stop this autoimmunity for decades, looking past blood sugar control to the actual cause of the mess.
Now, a team at the Medical University of South Columbia (MUSC) might have cracked a piece of it. At least, in mice.
Engineering Resilience
The lead researcher is Hongjun Wang, an associate director at the SCCT Institute Pilot Program. Her team published their work in Molecular Therapy. They used an experimental stem cell therapy to reverse newly diagnosed Type 1 diabetes in mouse models.
Standard stem cell treatments, specifically mesenchymal stem cells or MSCs, have shown promise in earlier trials. They can help preserve whatever insulin production is left. But there is a catch. The inflammation in a diabetic body is aggressive. It burns out the stem cells before they can do any real good.
So Wang’s team tweaked the cells.
They engineered MSCs to overproduce a protein called alpha-1 antitrypsine, or AAT. It’s a shield. The modified cells, called AAT-MSCs, became tougher. More resilient.
“While insulin injections are lifesaving… This study suggests a new way… by addressing the root cause rather than just managing blood sugar,” said Wang.
The double-whammy approach did two things at once. It protected the remaining beta cells in the pancreas. It also calmed the immune storm. Co-senior author Dr. Charlie Strange noted this combination makes the therapy significantly more potent than the standard version.
Rewiring the Response
The real story isn’t just survival. It’s reprogramming.
The team looked under the microscope at thousands of individual immune cells. They weren’t just looking for a quiet response. They wanted to see how the system was changing.
The immune system has a battlefield here. On one side, you have CD8+ killer T-cells. The aggressors. They destroy beta cells. On the other, you have T-regulatory cells. The peacekeepers. In Type 1 diabetes, the peacekeepers exist but they get overwhelmed. Drowned out by the attack.
After injecting the AAT-MSCs, the balance shifted. Drastically.
The number of protective regulatory cells spiked. The attacker cells didn’t just leave, they got tired. Pushed into exhaustion.
It worked. In mice.
And here is the weirder part. The stem cells don’t hang around.
They disappear within hours or days. Gone. Yet, the immune changes stuck.
“To impact or cure T1D, stem cells themselves do not need to be there,” Wang said. “This means the effect can last six to two years…”
It’s possible the dying cells release some microscopic factors that keep working after the host cells are dead. Like a letter that keeps arriving after the writer is gone.
Human Hopes and Harsh Realities
This study focused on new-onset diabetes. A window where some beta cells might still be salvageable. Wang’s team is currently testing this safety profile in humans. The earlier work got a boost from an SCTR Discovery Grant.
Could this apply to other diseases? Wang thinks so. Lupus. Chronic pancreatitis. Other inflammatory messes. The mechanism seems transferable.
But don’t celebrate too early. This is mice. It’s early stage. A lot more research sits between these results and your local clinic.
Wang wants a large multicenter trial next. There is hope, actually, for long-term diabetics. Studies suggest you might still have functioning beta cells hiding in the wreckage even years later.
If they can wake those cells up? If they can keep them safe?
The future of diabetes treatment might look less like a daily needle and more like a reset button. We just don’t know if that button works for humans yet.
